NCT00200382终止2 期
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Rasim Gucalp10 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2004年5月最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 27
- 试验地点
- 10
- 主要终点
- Response rate
研究概览
简要总结
The purpose of this study is to develop new treatments that will hopefully result in the relief of symptoms and prolongation of life. For this reason, your doctors have offered you treatment with a new experimental drug called PS 341.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have confirmed NSCLC (squamous, adeno- and large cell anaplastic carcinoma)stage III B or Stage IV.
- •No prior chemotherapy regimen Patients must have adequate organ and marrow function
排除标准
- •Untreated symptomatic brain metastasis Patients with known HIV positivity
结局指标
主要结局
Response rate
次要结局
未报告次要终点
研究者
Rasim Gucalp
Prof. Dept of Medicine (Oncology)
Montefiore Medical Center
研究点 (10)
Loading locations...
相似试验
已完成
1 期
Phase I/II Study of Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT00534664University of Sao Paulo40
已完成
2 期
ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer StudyNon Small Cell Lung CancerLung CancerNCT00745875AstraZeneca66
已完成
2 期
Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.Myelodysplastic SyndromesNCT01718379Groupe Francophone des Myelodysplasies132
进行中（未招募）
2 期
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesGastrointestinal Tract MalignanciesNCT05329766Arcus Biosciences, Inc.332
撤回
2 期
Evaluation of Efficacy and Safety of the Concomitant of RUTI® Immunotherapy With the Standard Treatment in TB PatientsTuberculosisNCT05136833Archivel Farma S.L.